Document is current
Any future updates will be listed below
-
Authors
Ebright, Richard Y. https://orcid.org/0000-0001-8975-5810
Zachariah, Marcus A.
Micalizzi, Douglas S. https://orcid.org/0000-0002-0306-9914
Wittner, Ben S. https://orcid.org/0000-0001-5657-9849
Niederhoffer, Kira L.
Nieman, Linda T.
Chirn, Brian
Wiley, Devon F.
Wesley, Benjamin
Shaw, Brian
Nieblas-Bedolla, Edwin
Atlas, Lian
Szabolcs, Annamaria https://orcid.org/0000-0003-4951-9914
Iafrate, Anthony J.
Toner, Mehmet
Ting, David T. https://orcid.org/0000-0002-3261-2322
Brastianos, Priscilla K. https://orcid.org/0000-0003-4470-8425
Haber, Daniel A. https://orcid.org/0000-0003-1378-6551
Maheswaran, Shyamala https://orcid.org/0000-0002-9356-1709
-
Funding
Funding for this research was provided by:
American Cancer Society (132140-PF-18-127-01-CSM)
U.S. Department of Health & Human Services | National Institutes of Health (2U01EB012493, U01CA214297, 2R01CA129933, 2U01EB012493, U01CA214297, U01CA214297)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Breast Cancer Research Foundation
Howard Hughes Medical Institute
National Foundation for Cancer Research
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 31 March 2020
Accepted: 10 November 2020
First Online: 9 December 2020
Competing interests
: D.T.T., M.T., D.A.H., and S.M. are founders of and own equity in TellBio, Inc., which is involved with CTC therapeutics and diagnostic. At this time, there has been no funding received or license that has been given to TellBio, Inc. for this work. D.T.T. is also a founder and owns equity in ROME Therapeutics and PanTher Therapeutics, which is not related to this work. D.T.T. has received consulting fees from ROME Therapeutics, Foundation Medicine, Inc., NanoString Technologies, EMD Millipore Sigma, and Pfizer that are not related to this work. D.T.T. receives research support from ACD-Biotechne, PureTech Health LLC, Ribon Therapeutics, which was not used in this work. D.T.T.’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. P.K.B. has received research support (to Massachusetts General Hospital) from Merck, Pfizer, Lilly, and BMS. P.K.B. has consulted for Genentech-Roche, ElevateBio, Lilly, and AngioChem. P.K.B. has received Speaker’s Honoraria from Genentech-Roche and Merck. R.Y.E. has received consulting fees from Nextech Invest and nference Inc., which are not related to this work. The other authors declare no competing interests.
